key: cord-1044615-o0gymxv7
authors: Katsiki, Niki; Ferrannini, Ele
title: Anti-inflammatory properties of antidiabetic drugs: a “promised land” in the COVID-19 era?
date: 2020-08-26
journal: J Diabetes Complications
DOI: 10.1016/j.jdiacomp.2020.107723
sha: 6e10306656e2fb2e8a04da4fd7a29b90deb0d53a
doc_id: 1044615
cord_uid: o0gymxv7

Inflammation is implicated in the development and severity of the coronavirus disease 2019 (COVID-19), as well as in the pathophysiology of diabetes. Diabetes, especially when uncontrolled, is also recognized as an important risk factor for COVID-19 morbidity and mortality. Furthermore, certain inflammatory markers [i.e. C-reactive protein (CRP), interleukin-6 (IL-6) and ferritin] were reported as strong predictors of worse outcomes in COVID-19 positive patients. The same biomarkers have been associated with poor glycemic control. Therefore, achieving euglycemia in patients with diabetes is even more important in the era of the COVID-19 pandemic. Based on the above, it is clinically interesting to elucidate whether antidiabetic drugs may reduce inflammation, thus possibly minimizing the risk for COVID-19 development and severity. The present narrative review discusses the potential anti-inflammatory properties of certain antidiabetic drugs (i.e. metformin, pioglitazone, sitagliptin, linagliptin, vildagliptin, alogliptin, saxagliptin, liraglutide, dulaglutide, exenatide, lixisenatide, semaglutide, empagliflozin, dapagliflozin, canagliflozin), with a focus on CRP, IL-6 and ferritin.

Inflammation plays a key role in the development and severity of the new coronavirus disease 2019 (COVID-19) 1 . Indeed, severe COVID-19 pneumonia is related to systemic hyperinflammation (or cytokine storm) 2 . Serum C-reactive protein (CRP), interleukin-6 (IL-6) and

ferritin have been recognized as strong predictors of the COVID-19 severity and mortality [3] [4] [5] .

Diabetes is also considered as a significant risk factor for COVID-19 morbidity and mortality 6 .

Indeed, a recent meta-analysis (83 studies, n=78,874 hospitalized patients with confirmed COVID-19) reported that pre-existing diabetes almost doubled the risk for severe/critical COVID-19 [n=22 studies; odds ratio (OR) 2.10, 95% confidence interval (95%CI) 1.71-2.57] and almost tripled in-hospital mortality (OR 2.68, 95%CI 2.09-3.44) 7 . Similar results were reported in another meta-analysis (33 studies, n=16,003 patients) for both COVID-19 severity (OR 2.75, 95%CI 2.09-3.62) and mortality (OR 1.90, 95%CI 1.37-2.64) 8 . Furthermore, chronic, low-grade inflammation is associated with insulin resistance and hyperglycemia 9-11 , and inflammatory markers, such as CRP, IL-6 and ferritin, have been quantitatively related to HbA 1c [12] [13] [14] . This highlights the importance of achieving euglycemia in patients with diabetes, especially in the era of COVID-19.

Based on the above, it is relevant to establish whether antidiabetic therapies may reduce the inflammatory reaction, thus possibly minimizing the risk for COVID-19 development and severity. The present narrative review discusses the potential anti-inflammatory properties of Metformin mechanism of action classically involves both AMP-activated protein kinase (AMPK)-independent and AMPK-dependent pathways 15 . In many studies, this drug has been shown to inhibit mitochondrial respiration as well as mitochondrial glycerophosphate dehydrogenase, leading to suppression of ATP production and hepatic gluconeogenesis, whereas AMPK activation enhances catabolic pathways generating ATP and switches off cellular processes consuming ATP 15, 16 .

There is basic and clinical evidence for an anti-inflammatory action of metformin 17 .

Metformin was also shown to suppress the secretion of proinflammatory cytokines in hepatocytes and macrophages 18 . Among 77 . Similarly, saxagliptin did not affect the secretion of IL-6 from adipocytes in 40 non-diabetic overweight/obese patients followed for 6 weeks 78 . No data on ferritin and saxagliptin exist.

GLP-1 RAs promote insulin secretion by the beta-cells and inhibit glucagon secretion by the alpha-cells of the pancreas 79 . GLP-1 RAs also delay gastric emptying and suppress food intake 79 . GLP-1 RAs have been reported to exert anti-inflammatory properties via several molecular mechanisms, both in vivo and in vitro 80 .

Liraglutide has been reported to exert antioxidant and anti-inflammatory effects in vitro 81, 82 as well as in T2DM patients 83 

There are limited data on dulaglutide, CRP and IL-6. In one study, 755 T2DM patients were randomized to receive either dulaglutide once weekly (0.75 or 1.5 mg) or placebo; changes from baseline in hsCRP levels at 16 weeks were -0.98, -0.08 and 0.62 mg/l for dulaglutide 1.5 mg (p<0.001 compared with placebo), dulaglutide 0.75 mg, and placebo, respectively 98 . In another smaller study, once weekly dulaglutide (0.75 mg in 8 T2DM patients and 1.5 mg in 5 patients) led to a significant reduction in serum IL-6 levels (from 1.42 ± 0.84 to 0.31 ± 0.23 pg/mL, p<0.001) at 26 weeks 99 . No study investigated the effects of dulaglutide on ferritin.

Exenatide reduced circulating markers of oxidative stress and inflammation in T2DM patients 100, 101 . In 61 T2DM patients on exenatide (5 or 10 mcg twice daily) for a mean of 1.4 years, circulating CRP levels decreased from 5.1 ± 1.7 to 2.7 ± 1.2 mg/L (p<0.001) 102 .

Similarly, serum hsCRP was lowered by 34% (p=0.05) in 38 T2DM patients taking exenatide (5 J o u r n a l P r e -p r o o f Journal Pre-proof mcg twice per day) for a mean of 26 weeks 103 . In another study involving 23 T2DM patients (11 patients on placebo and 12 patients on exenatide 5 μg twice daily for 4 weeks, followed by 10 μg twice daily for 12 weeks), hsCRP was significantly reduced in the exenatide group (-37%) compared with placebo (+137%) 100 . Exenatide therapy for 1 year also led to lower hsCRP levels (from 1.81±0.25 to 1.30±0.22 mg/L, p=0.008) in 30 T2DM patients 104 .

Circulating IL-6 levels fell from 3.01±0.49 to 2.07±0.57 pg/mL (p<0.05) after 12 weeks of exenatide treatment (10 μg twice daily) in 12 T2DM patients 105 . In another study, 18 T2DM patients received exenatide for 3 months (5 μg twice daily for the first month, followed by 10 μg for the next 2 months); serum IL-6 concentrations were reduced from 15.69±10.86 ng/mL at baseline to 10.76±5.15 ng/mL at 3 months (p=0.001) 106 . No data on the effects of exenatide on ferritin are currently available.

Lixisenatide was reported to downregulate the expression of proinflammatory cytokines, including IL-6, in human fibroblast-like synoviocytes and in primary chondrocytes 107, 108 . No human study evaluated the impact of lixisenatide on CRP, IL-6 and ferritin.

In a 52-week weight management trial (n=957 non-diabetic obese patients randomized to oral semaglutide 0.05-0.4 mg/day or placebo), hsCRP was reduced by up to 43% vs placebo in all semaglutide groups at week 52; these reductions were either significant or close to significance 109 . However, statistical significance was lost after adjustment for change in body weight 109 and, subsequently, lowering plasma glucose levels 111, 112 . Potential anti-inflammatory effects have been reported for SGLT2i 113 .

Among 50 T2DM patients with CAD, empagliflozin 10 mg/day significantly lowered CRP at 6 months (from 0.11 to 0.07 mg/dL, p=0.003) 114 . Empagliflozin 10 mg/day for 12 months also notably reduced hsCRP by 54% (from 1.33 to 0.59 mg/L, p=0.007) in 51 T2DM patients 115 .

However, in another study with 58 T2DM patients receiving empagliflozin 25 mg/day for 6 weeks, no significant changes in hsCRP levels were found (2.10±1.72 vs 1.99±1.19 mg/L, baseline vs 6 weeks, respectively) 116 .

Interestingly, empagliflozin was reported to decrease markers of oxidative stress and inflammation (including IL-6) in the lungs of mice, thus suggesting a role in preventing pulmonary fibrosis 117 , as well as in rat cardiomyoblasts (including reduction of IL-6 expression), thus potentially minimizing infarct size 118 . Similarly, in diabetic rats empagliflozin exhibited anti-oxidant and anti-inflammatory effects in the kidneys; urinary IL-6 levels were also lowered 119 . Overall, experimental data strongly support a protective role of empagliflozin against cardiac and renal inflammation 120,121 . However, clinical evidence is lacking. There is one study reporting that empagliflozin significantly reduced circulating IL-6 levels in 32 men T2DM patients; this IL-6-lowering effect of empagliflozin was greater than that of canagliflozin 122 .

In a large-scale proteomics study, empagliflozin 25 mg/day led to significant decreases in circulating ferritin levels after 4 weeks of treatment 123 . Furthermore, a sub-study of the EMPA-HEART CardioLink-6 randomized clinical trial, involving 82 T2DM patients with CAD, showed that 6 months of empagliflozin treatment (10 mg/day) was associated with a significant reduction in ferritin levels (mean difference -21.83 µg/L, 95%CI: -37.96, -5.7; p=0.008) 124 .

In animal studies, dapagliflozin was shown to exert anti-oxidant and anti-inflammatory actions in the kidney, liver and lungs 125,126 . There is also data supporting a CRP-lowering effect of dapagliflozin in humans 127 . In this context, dapagliflozin 10 mg/day combined with metformin significantly lowered CRP (from 6.2±1.1to 3.1±0.7 mg/L, p<0.05) in 59 T2DM

patients at 12 weeks 26 as did dapagliflozin 5 mg/day after 12 weeks (from 2410±2814 to 1607±1960 ng/mL, p<0.01) in 27 T2DM patients 128 . In contrast, among 11 T2DM patients with non-alcoholic steatohepatitis, treatment with dapagliflozin 5 mg/day for 24 weeks led to a nonsignificant reduction in hsCRP 129 . Furthermore, another study reported a significant increase in median hsCRP levels in 36 T2DM patients treated with dapagliflozin (10 mg/day) for 12 weeks (from 1.93 to 6.03 mg/L, p=0.009) 130 .

In a randomized, placebo-controlled study (n=32 T2DM patients), 8 weeks of dapagliflozin (10 mg/day) therapy led to a significant placebo-corrected reduction in IL-6 levels (by -1.87 pg/mL, p<0.05) 131 

A proteomic model found that canagliflozin 300 mg/day significantly lowered plasma IL-6 concentrations (by 26.6%, p=0.010) 138 . Similar results were reported in animal studies 139,140 .

However, in human studies no significant changes in IL-6 levels have been found following treatment with canagliflozin (100 mg/day, 24 weeks) 122, 141 . In contrast, canagliflozin 300 mg/day for 52 weeks was shown to significantly lower serum IL-6 (by 22%) in 100 T2DM patients 135 .

In a small study (9 T2DM patients), canagliflozin 100 mg/day for 12 weeks led to a significant decrease in median ferritin levels (from 72 to 55 ng/mL, p=0.003) 142 . Furthermore, serum ferritin concentrations were significantly and progressively lowered from baseline to 3 and 6 months (from 184.9 to 143.8 and 117.3 ng/mL, respectively, p<0.05) in 35 canagliflozin (100 mg/day)-treated NAFLD patients 143 . Similar results were also reported in T2DM patients with biopsy-proven NASH 144 . Of note, SGLT2i have been suggested for NAFLD/NASH treatment [145] [146] [147] as is the case for pioglitazone and GLP-1 RAs 148, 149 .

Overall, diabetes has been closely linked to inflammation 150 . Furthermore, HbA 1c has been positively related to hsCRP, IL-6 and ferritin levels [151] [152] [153] [154] [155] , thus supporting also a role for euglycemia in reducing chronic inflammation in patients with diabetes. Apart from antidiabetic drugs, a healthy lifestyle (including diet, exercise and no smoking) can contribute to glucose and inflammation control 156, 157 . Interestingly, HbA 1c level was positively associated with inflammation and hypercoagulability, as well as negatively associated with SaO2 in COVID-19

infected patients 158 , thus further highlighting the importance of achieving glucose control in the COVID-19 era.

Despite the multitude of reports, the data here analyzed (summarized in Table 1 for the human studies) fall short of providing good evidence for a clinically significant antiinflammatory effect of the most common antidiabetic classes of medication for several reasons.

Firstly, studies were frequently small in size or detecting small differences. Secondly, many Thirdly, studies of similar design yielded contrasting results for one or the other biomarker, or inconsistent findings across biomarkers. Finally, and perhaps more importantly, most studies did not control, or were not equipoised, for the anti-hyperglycemic effect, so that a bona fide pharmacologic effect of a given drug cannot be distinguished from a non-specific effect of improved glycemia.

With all these limitations, perhaps the most suggestive data are those on ferritin for the SGLT2 inhibitors, which may be related to enhanced erythropoiesis rather than tissues inflammation. In any event, large, multiethnic, equipoised trials would be required to determine whether certain antidiabetic drugs exert inherent anti-inflammatory properties above and beyond their antihyperglycemic efficacy; the latter remains decidedly useful in COVID-19 disease.

NK has given talks, attended conferences and participated in trials sponsored by Astra 

C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus

Inflammatory markers and control of type 2 diabetes mellitus

C-reactive protein and glycemic control in adults with diabetes

Correlation between changes in inflammatory cytokines and the combination with hypertension in patients with type 2 diabetes mellitus

The mechanisms of action of metformin

Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo

Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect

SAVOR-TIMI 53 Steering Committee and Investigators. Heart failure, saxagliptin, and diabetes mellitus:observations from the SAVOR-TIMI 53 randomized trial

Effects of saxagliptin on adipose tissue inflammation and vascular function in overweight and obese people: a placebo-controlled study

Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1

Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control

Liraglutide suppresses TNF-α-induced degradation of extracellular matrix in human chondrocytes: a therapeutic implication in osteoarthritis

The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells

Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease

Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease

Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial

Clinical use of liraglutide in type 2 diabetes and its effects on cardiovascular risk factors

Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease Creactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial

Beneficial effects of once-daily liraglutide, a human glucagonlike peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes

Liraglutide improves insulin sensitivity in high fat diet induced diabetic mice through multiple pathways

Beneficial effects of liraglutide (GLP1 analog) in the hippocampal inflammation

Meta-analysis of the efficacy of liraglutide in patients with type 2 diabetes accompanied by incipient nephropathy

Liraglutide treatment reduced interleukin-6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathy

peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus

A Randomized Study to Compare the Effects of Once-Weekly Dulaglutide Injection and Once-Daily Glimepiride on Glucose Fluctuation of Type 2 Diabetes Mellitus Patients: A 26-Week Follow-Up

Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus

Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reduction

Durability of effects of exenatide treatment on glycemic control, body weight, systolic blood pressure, C-reactive protein, and triglyceride concentrations

Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin

Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition

Comparison of exenatide and acarbose on intra-abdominal fat content in patients with obesity and type-2 diabetes: A randomized controlled trial

The protective effects of lixisenatide against inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes

Lixisenatide attenuates advanced glycation end products (AGEs)-induced degradation of extracellular matrix in human primary chondrocytes

Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity

Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial

Sodium-Glucose Co-transporters and Their Inhibition: Clinical 113

Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys

Empagliflozin's Ameliorating Effect on Plasma Triglycerides: Association with Endothelial Function Recovery in Diabetic Patients with Coronary Artery Disease

Anti-inflammatory effects of empagliflozin in patients with type 2 diabetes and insulin resistance

Targeting oxidative stress, proinflammatory cytokines, apoptosis and toll like receptor 4 by empagliflozin to ameliorate bleomycin-induced lung fibrosis

Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats

Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways

Empagliflozin and canagliflozin attenuate inflammatory cytokines interferon-λ, tumor necrosis factor-α, interleukin-6: possible mechanism of decreasing cardiovascular risk in diabetes mellitus

Mechanisms of sodium-glucose cotransporter-2 inhibition: insights from large-scale proteomics

The SGLT

Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE

Dapagliflozin: more than just another oral glucose-lowering agent?

Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus Patients

Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study

Diabetes With Established Ischemic Heart Disease (EDIFIED)

Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease

Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis

Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes

Canagliflozin on Urinary Albumin Excretion in Japanese Patients with Type 2 Diabetes Mellitus and Microalbuminuria: A Pilot Study

Canagliflozin for Japanese patients with chronic heart failure and type II diabetes

Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease

Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on cisplatin-induced nephrotoxicity in mice

Effect of canagliflozin on the overall clinical state including insulin resistance in Japanese patients with type 2 diabetes mellitus

Canagliflozin Improves Erythropoiesis in Diabetes Patients with Anemia of Chronic Kidney Disease

Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study

Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1-3 fibrosis

Non-Alcoholic Fatty Liver Disease 147

Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: Effects of statins and antidiabetic drugs

Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!

The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk

Inflammation in the Pathophysiology and Therapy of Cardiometabolic Disease

Is serum Creactive protein concentration correlated with HbA1c and insulin resistance in Type 2 diabetic men with or without coronary heart disease

Serum ferritin level is higher in poorly controlled patients with type 2 diabetes and people without diabetes, aged over 55 years

Analysis of inflammatory mediators in type 2 diabetes patients

Low-grade inflammation, diet composition and health: current research evidence and its translation

Anti-inflammatory effects of exercise: role in diabetes and cardiovascular disease

Glycosylated hemoglobin is associated with systemic inflammation, hypercoagulability, and prognosis of COVID-19 patients